glp1 gip tirzepatide dual agonist is a first-in-class targeting both and GLP-1 receptors, offering Bumps and humps in the

Among the GLP-1 analogs, tirzepatide showed the most pronounced decrease in respiratory quotient (RQ) (Fig

explored the impact of BBR on adipose tissue and renal function using 3T3-L1 cells and spontaneously hypertensive rats

Orforglipron (Foundayo): Early data suggests plateaus at 6 to 10 months, with 14 to 17 percent weight loss in maintenance trials

This performance trails injectable semaglutide (Wegovy) by 2 to 3 percentage points, which translates to about 5 to 7 fewer pounds lost for a 200-pound person

months) The reasons for switching the GLP-1RA therapies were categorized into treatment-related discontinuations (i.e., injection burden, non-response), symptom-related (i.e., nausea, vomiting, dyspepsia, diarrhea, constipation, malnutrition), and access/coverage-related (shortage, insurance denial)